statistiche ricercatore

AGENO, WALTER

Distribuzione geografica

Continente	#
NA - Nord America	42.356
EU - Europa	22.084
AS - Asia	5.305
Continente sconosciuto - Info sul continente non disponibili	55
SA - Sud America	38
OC - Oceania	23
AF - Africa	12
Totale	69.873

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	42.308
IT - Italia	11.427
UA - Ucraina	4.067
TR - Turchia	2.780
SE - Svezia	1.797
DE - Germania	1.506
VN - Vietnam	1.398
IE - Irlanda	1.228
CN - Cina	966
FI - Finlandia	721
GB - Regno Unito	699
FR - Francia	276
RU - Federazione Russa	154
IN - India	66
EU - Europa	53
CA - Canada	43
BE - Belgio	39
NL - Olanda	38
JP - Giappone	34
CZ - Repubblica Ceca	33
AU - Australia	18
BR - Brasile	18
ES - Italia	16
PT - Portogallo	13
SG - Singapore	13
CH - Svizzera	12
CL - Cile	10
RO - Romania	9
HK - Hong Kong	8
PL - Polonia	8
EG - Egitto	7
IR - Iran	7
MY - Malesia	7
AT - Austria	6
IL - Israele	6
AR - Argentina	5
HU - Ungheria	5
NZ - Nuova Zelanda	5
GR - Grecia	4
LK - Sri Lanka	4
MK - Macedonia	4
BG - Bulgaria	3
CO - Colombia	3
DK - Danimarca	3
MX - Messico	3
TW - Taiwan	3
AL - Albania	2
EE - Estonia	2
HR - Croazia	2
ID - Indonesia	2
KW - Kuwait	2
KZ - Kazakistan	2
LI - Liechtenstein	2
NG - Nigeria	2
NO - Norvegia	2
SI - Slovenia	2
A1 - Anonimo	1
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
BY - Bielorussia	1
CR - Costa Rica	1
DZ - Algeria	1
IQ - Iraq	1
KE - Kenya	1
KR - Corea	1
MD - Moldavia	1
MM - Myanmar	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
PR - Porto Rico	1
RS - Serbia	1
TH - Thailandia	1
TN - Tunisia	1
Totale	69.873

Salva come PNG Salva come JPEG

Città	#
Milan	8.474
Fairfield	7.198
Woodbridge	4.799
Houston	3.518
Ashburn	3.507
Jacksonville	3.301
Seattle	2.793
Wilmington	2.600
Cambridge	2.459
Ann Arbor	2.425
Chandler	2.236
Izmir	1.393
Princeton	1.350
Dublin	1.220
Dearborn	961
Dong Ket	683
Nyköping	664
Rome	620
San Diego	398
San Mateo	308
Ogden	261
Como	183
Washington	164
Beijing	159
London	139
Düsseldorf	137
Hefei	124
Redmond	122
Nanjing	95
Kocaeli	88
New York	86
Kunming	81
Verona	80
Norwalk	75
Boardman	67
Los Angeles	59
Nanchang	56
Jinan	50
Dallas	45
Guangzhou	42
Kilburn	39
Falls Church	38
Helsinki	36
Besana In Brianza	33
Brussels	32
Tokyo	32
Philadelphia	30
Fuzhou	29
Brno	28
Munich	27
Prescot	27
Redwood City	26
Chiswick	25
Frankfurt am Main	25
Toronto	23
Berlin	22
Chicago	22
Shenyang	22
Acton	20
New Bedfont	20
Zhengzhou	20
Phoenix	19
Ponte Lambro	19
Detroit	18
Wandsworth	18
Hounslow	17
Pune	15
Wuhan	15
Xian	15
Islington	14
Southwark	14
São Paulo	14
Changsha	13
Chengdu	13
Indiana	13
Lappeenranta	13
San Francisco	13
Auburn Hills	12
Hebei	12
Andover	11
Ningbo	11
Quzhou	11
Saint Petersburg	11
Shaoxing	11
Chongqing	10
Busto Arsizio	9
Shanghai	9
Stockholm	9
Suresnes	9
Bangalore	8
Baotou	8
Bologna	8
Florence	8
Madrid	8
Paris	8
Ralingen	8
Singapore	8
Hangzhou	7
Hanoi	7
Amsterdam	6
Totale	54.048

Salva come PNG Salva come JPEG

Nome	#
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes	260
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study	241
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	235
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	222
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	222
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	218
Risk of recurrence of unusual site venous thromboembolism	211
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	200
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review	196
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients	195
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	192
Breadth of complications of long-term oral anticoagulant care	191
Abdominal obesity and the risk of recurrent deep vein thrombosis	190
Optimal treatment duration of venous thrombosis	188
Management of recurrent venous thromboembolism in cancer patients	188
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	187
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	186
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry	186
Patient selection for thromboprophylaxis in medical inpatients	184
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial	183
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	183
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	181
Prevention and treatment of venous thromboembolism	179
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	179
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	178
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure”	177
Exaggerated initial response to warfarin following heart valve replacement	176
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	176
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	176
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	176
Venous ischemic syndromes	176
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	174
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review	174
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study	173
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	172
Management of incidental splanchnic vein thrombosis in cancer patients	172
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	172
Warfarin interactions with antibiotics in the ambulatory care setting	169
Treating patients with cancer and acute venous thromboembolism	169
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	169
Duration of anticoagulation after venous thromboembolism in real world clinical practice	168
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	168
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	168
Managing challenging patients with venous thromboembolism: A practical, case-based approach	168
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study	167
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications	167
Venous and arterial thrombosis in patients with HIV infection	166
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients	166
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation	166
Update on the diagnosis and management of pulmonary embolism	166
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients	165
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty	165
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study	165
Direct oral anticoagulants in rare venous thrombosis	165
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism	164
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	164
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH	162
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice.	161
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE	161
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	161
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	161
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	161
Applying EBM in clinical practice	160
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis	160
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	160
Oral rivaroxaban for symptomatic venous thromboembolism	159
Statins and secondary prevention of ischemic and hemorrhagic stroke	159
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants	159
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	159
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	158
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	158
ABO blood group and vascular disease: an update	158
Spotlight on real-world evidence for the treatment of DVT: XALIA	158
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	158
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	158
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	157
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study	157
Dabigatran in clinical practice: Contemporary overview of the evidence	156
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	156
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial	156
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies	155
Guidance for the management of venous thrombosis in unusual sites	155
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide	155
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	154
JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.	154
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	154
Is diabetes a hypercoagulable state? A critical appraisal	154
Venous thromboembolism: Past, present and future	154
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	153
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation	153
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	153
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	153
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	152
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events	151
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin?	151
Prevention of in-hospital VTE: why can't we do better?	150
How I treat splanchnic vein thrombosis	150
The role of thrombolytic therapy in pulmonary embolism	150
Statins for acute ischemic stroke	150
Extended oral anticoagulant therapy after a first episode of pulmonary embolism	149
Totale	17.097

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	271.332
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	271.332

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	13.969	0	679	753	2.942	986	1.555	2.116	1.734	1.148	917	259	880
2020/2021	13.656	231	1.104	1.560	1.768	972	1.396	543	1.226	1.503	803	953	1.597
2021/2022	6.828	757	872	355	182	402	376	337	375	386	1.267	644	875
2022/2023	6.740	824	258	431	650	510	1.571	19	787	1.024	268	191	207
2023/2024	13.559	2.152	2.188	2.195	2.612	2.767	824	95	147	391	79	37	72
2024/2025	136	69	67	0	0	0	0	0	0	0	0	0	0
Totale													70.737